Jefferies Starts Verastem (VSTM) at Buy, $21 PT

July 29, 2013 7:00 AM EDT Send to a Friend
Get Alerts VSTM Hot Sheet
Price: $9.80 +4.14%

Rating Summary:
    11 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 27 | Down: 26 | New: 17
Trade VSTM Now!
Join SI Premium – FREE
Jefferies initiates coverage on Verastem (NASDAQ: VSTM) with a Buy. PT $21.00.

Analyst Biren Amin comments, "VSTM's R&D focus is the development of drugs targeting cancer stem cells. VSTM will begin a registration-directed PII trial for its lead candidate, VS-6063 (FAK inhibitor), in mesothelioma that we believe has favorable odds of showing a PFS benefit, supporting potential accelerated approval in H2'16."

For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.

Shares of Verastem closed at $14.78 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Jefferies & Co

Add Your Comment